Information Provided By: 
Fly News Breaks for March 28, 2019
SRPT
Mar 28, 2019 | 10:54 EDT
Piper Jaffray analyst Danielle Brill raised her price target on Sarepta shares to $208 from $200 after the company reported what she said was "positive" bio-marker data with its exon 45 skipping candidate casimersen. She anticipates approval and launch by the first half of 2020 and estimates casimersen revenues of about $170M in 2021 before gene therapy becomes available, the analyst noted. Brill keeps an Overweight rating on Sarepta shares.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
